Giannis Mountzios
@g_mountzios
#MedicalOncologist MSc Transl Res Univ Paris Sud #LungCancer biology, immunotherapy, clinical trials #LCSM @myESMO faculty @iaslc live to give
Being part of a history-making drug that helps pts with #SCLC live longer and better is the biggest reward a thoracic oncologist could hope for. Grateful being involved and to our pts Just out in @NEJM Presentation today by 1@only @charlesrudin #ASCO25
Sherlock-Lung: Mutagenesis of LC in Never Smokers (LCNS) @Nature: - 871pt samples - KRAS+ ⬆️3.8x in LCNS’s in USA/EU v Asia - passive smoke not assoc with mtns - air pollution (PM2.5) assoc with p53 & shorter telomeres @OncoAlert #LCSM nature.com/articles/s4158…
In NSCLC & AGA we usually use the ⬆️ dose of targeted therapies despite no always correlation btw dose and efficacy or intracranial activity.In this review, we discuss these topics. Is time to redefine doses of TT as now applied across stages? doi.org/10.1016/j.ctrv…
Datopotamab deruxtecan is now FDA approved for EGFR-mutant #NSCLC after prior EGFR & platinum therapy. In this episode of #LungCancerConsidered, @NarjustFlorezMD and @sands_jacob break down the data and clinical implications of this exciting development. 🎧…
A state-of-the-art Review on #EGFR mutant #NSCLC in the most prestigious journal in the world. A must-read for all thoracic oncologists! I enjoyed every single 📖 Congratulations @Alfdoc2 @LeXiuning @stephanieplsaw @gbanna74 and all co-authors, this will be the reference paper…
Hot off the press a 🚨 Must-read review on optimizing treatment for #LungCancer with activating EGFR mutations , a true game changer in targeted therapy. TKIs have transformed outcomes, but the journey continues. 👉 acsjournals.onlinelibrary.wiley.com/doi/full/10.33… thanks to all the co-authors, great team…
Fantastic work together with @Alfdoc2 @jillfeldman4 and my global colleagues. Now we have identified clinical and molecular poor prognostic factors, we just have to push forward to improve outcomes for those patients. @MDAndersonNews @lungoncdoc @OncoViews @oncodaily
Hot off the press a 🚨 Must-read review on optimizing treatment for #LungCancer with activating EGFR mutations , a true game changer in targeted therapy. TKIs have transformed outcomes, but the journey continues. 👉 acsjournals.onlinelibrary.wiley.com/doi/full/10.33… thanks to all the co-authors, great team…
🔥🚨HOT OFF THE PRESS Published @JCO_ASCO TWO @ASCO Living #Guideline updates Version 2025.1 by great experts on: Therapy for Stage IV Non-Small Cell #LungCancer: 1) WITHOUT Driver Alterations 👉 brnw.ch/21wUfz5 2) WITH Driver Alterations 👉 brnw.ch/21wUekt
Randomized Ph II trial: 6m consolidation nivo (N) or ipi/nivo (I/N) in stage III unresectable NSCLC @jitcancer - 18m-PFS 65.5% N, 66.3% I/N - mOS 32m, NR - g3+ TRAE 18.5% v 29.4% Congrats @gdurm @BigTenCRC 🏆, pleased to contribute as @HopkinsThoracic PI jitc.bmj.com/content/13/7/e…
That feeling when 7+ years of work lands on the front page of @NEJM—and one of the people I respect most, @KoheiShitara , writes the editorial. Honored to share this moment with you, Kohei. Here’s to a decade of friendship, and curing gastric cancer. #Matterhorn @MSKCancerCenter
It’s my great honor to write the editorial for the pivotal MATTERHORN study @NEJM @YJanjigianMD @ASCO More global collaboration is needed to further improve outcomes for our patients with gastric/GEJ cancer.@OncoAlert @oncodaily nejm.org/doi/full/10.10…
1/11 Our study on subclonal immune evasion in non-small cell lung cancer has just been published in @Cancer_Cell cell.com/cancer-cell/fu…
Do you want to sub-specialise in lung cancer? Please come and work with me and the Lung Team @TheChristieNHS and apply for an ESO fellowship. Deadline is mid September! For informal enquiries, please email [email protected] eso.net/en/career-deve…
Back in Zurich for another exceptional @etop_ibcsg workshop, now focusing on T-cell engagers (TCE) and their unprecedented benefit in #SCLC. An amazing group of colleagues who paved preclinical/clinical development discussed the presence and the future of TCEs. Watch this…
Day #2 @etop_ibcsg workshop Lessons from haematology about T-cell engagers 🔺 Several potential toxicities 🔺 Haemophagocytic syndrome ❗️ ✅ Combination with chemo possible ✅ Use CRS prophylaxis
A busy weekend here in #Barcelona with a brainstorming @etop_ibcsg meeting full of innovative concepts and new collaborations, followed by the Global Lung Cancer Summit recapitulating all important advances in 2024 by international experts!! Thrilled to meet friends around the…
Fantastic first day at the ETOP Workshop on T Cell Engagers. Reviewing the data, previewing the future, devising ways to overcome barriers to implementation. Great to engage with friends in Zurich! @etop_ibcsg
Out in @Nature the biggest effort to date to elucidate Genomic landscape in #lungcancer in neversmokers (NS) by @theNCI shedding light in genome-environmental interplay: ➡️ KRAS mut in NS from Europe/US 3.8 times more frequent compared to NS from East-Asia ➡️ Air pollution…
Make plans for #DCLung25 - Saturday, October 4th - Washington DC - a one-day @IASLC endorsed comprehensive lung cancer conference! Dr. Alfredo Addeo @Alfdoc2 joins from Switzerland to discuss bispecific antibodies and lung cancer. Register today! medstarhealth.org/dclung25
Honored and humbled to accept a new role as Division Chief for Hematology & Oncology at Georgetown starting next month. Excited for all that the future holds for @Georgetown @LombardiCancer with the best colleagues one could ask for.